Literature DB >> 29858864

Current understanding of the structure and function of family B GPCRs to design novel drugs.

Vlasios Karageorgos1, Maria Venihaki2, Stelios Sakellaris1, Michail Pardalos1, George Kontakis3, Minos-Timotheos Matsoukas4, Achille Gravanis1, Andreas Margioris2, George Liapakis5.   

Abstract

Family B of G-protein-coupled receptors (GPCRs) and their ligands play a central role in a number of homeostatic mechanisms in the endocrine, gastrointestinal, skeletal, immune, cardiovascular and central nervous systems. Alterations in family B GPCR-regulated homeostatic mechanisms may cause a variety of potentially life-threatening conditions, signifying the necessity to develop novel ligands targeting these receptors. Obtaining structural and functional information on family B GPCRs will accelerate the development of novel drugs to target these receptors. Family B GPCRs are proteins that span the plasma membrane seven times, thus forming seven transmembrane domains (TM1-TM7) which are connected to each other by three extracellular (EL) and three intracellular (IL) loops. In addition, these receptors have a long extracellular N-domain and an intracellular C-tail. The upper parts of the TMs and ELs form the J-domain of receptors. The C-terminal region of peptides first binds to the N-domain of receptors. This 'first-step' interaction orients the N-terminal region of peptides towards the J-domain of receptors, thus resulting in a 'second-step' of ligand-receptor interaction that activates the receptor. Activation-associated structural changes of receptors are transmitted through TMs to their intracellular regions and are responsible for their interaction with the G proteins and activation of the latter, thus resulting in a biological effect. This review summarizes the current information regarding the structure and function of family B GPCRs and their physiological and pathophysiological roles.

Entities:  

Keywords:  Antagonists; Binding; Family B GPCRs; Ligands; Physiological/pathophysiological role; Receptor activation; Signaling; Structure

Mesh:

Substances:

Year:  2018        PMID: 29858864     DOI: 10.1007/s42000-018-0009-5

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  14 in total

1.  Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.

Authors:  Oleg G Chepurny; Minos-Timotheos Matsoukas; George Liapakis; Colin A Leech; Brandon T Milliken; Robert P Doyle; George G Holz
Journal:  J Biol Chem       Date:  2019-01-08       Impact factor: 5.157

Review 2.  AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors.

Authors:  Xin-Heng He; Chong-Zhao You; Hua-Liang Jiang; Yi Jiang; H Eric Xu; Xi Cheng
Journal:  Acta Pharmacol Sin       Date:  2022-07-01       Impact factor: 6.150

3.  Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists.

Authors:  Sanaz Darbalaei; Ru-Lue Chang; Qing-Tong Zhou; Yan Chen; An-Tao Dai; Ming-Wei Wang; De-Hua Yang
Journal:  Acta Pharmacol Sin       Date:  2022-08-11       Impact factor: 7.169

4.  A new neuropeptide insect parathyroid hormone iPTH in the red flour beetle Tribolium castaneum.

Authors:  Jia Xie; Ming Sang; Xiaowen Song; Sisi Zhang; Donghun Kim; Jan A Veenstra; Yoonseong Park; Bin Li
Journal:  PLoS Genet       Date:  2020-05-04       Impact factor: 5.917

5.  The Glycosphingolipid GM3 Modulates Conformational Dynamics of the Glucagon Receptor.

Authors:  T Bertie Ansell; Wanling Song; Mark S P Sansom
Journal:  Biophys J       Date:  2020-06-17       Impact factor: 4.033

6.  AmOctα2R: Functional Characterization of a Honeybee Octopamine Receptor Inhibiting Adenylyl Cyclase Activity.

Authors:  Wolfgang Blenau; Joana Alessandra Wilms; Sabine Balfanz; Arnd Baumann
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

Review 7.  G protein-coupled receptors: structure- and function-based drug discovery.

Authors:  Dehua Yang; Qingtong Zhou; Viktorija Labroska; Shanshan Qin; Sanaz Darbalaei; Yiran Wu; Elita Yuliantie; Linshan Xie; Houchao Tao; Jianjun Cheng; Qing Liu; Suwen Zhao; Wenqing Shui; Yi Jiang; Ming-Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-01-08

8.  The Role of ICL1 and H8 in Class B1 GPCRs; Implications for Receptor Activation.

Authors:  Ian Winfield; Kerry Barkan; Sarah Routledge; Nathan J Robertson; Matthew Harris; Ali Jazayeri; John Simms; Christopher A Reynolds; David R Poyner; Graham Ladds
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-13       Impact factor: 5.555

9.  PaOctβ2R: Identification and Functional Characterization of an Octopamine Receptor Activating Adenylyl Cyclase Activity in the American Cockroach Periplaneta americana.

Authors:  Wolfgang Blenau; Anna-Sophie Bremer; Yannik Schwietz; Daniel Friedrich; Lapo Ragionieri; Reinhard Predel; Sabine Balfanz; Arnd Baumann
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

10.  Mutational Landscape of the Proglucagon-Derived Peptides.

Authors:  Peter Lindquist; Jakob S Madsen; Hans Bräuner-Osborne; Mette M Rosenkilde; Alexander S Hauser
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-17       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.